Net Income (Loss) Attributable to Parent in USD of AGILE THERAPEUTICS INC from 2012 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Agile Therapeutics Inc quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2012 to Q2 2024.
  • Agile Therapeutics Inc Net Income (Loss) Attributable to Parent for the quarter ending 30 Jun 2024 was -$11.9M, a 212% decline year-over-year.
  • Agile Therapeutics Inc Net Income (Loss) Attributable to Parent for the twelve months ending 30 Jun 2024 was -$15.9M, a 16.8% increase year-over-year.
  • Agile Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$14.5M, a 43.1% increase from 2022.
  • Agile Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$25.4M, a 64.2% increase from 2021.
  • Agile Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$71.1M, a 37.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

AGILE THERAPEUTICS INC Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$15.9M -$11.9M -$8.06M -212% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2024
Q1 2024 -$7.79M $1.28M +$6.67M 01 Jan 2024 31 Mar 2024 10-Q 12 Aug 2024
Q4 2023 -$14.5M -$4.47M -$539K -13.7% 01 Oct 2023 31 Dec 2023 10-K 28 Mar 2024
Q3 2023 -$13.9M -$799K +$5.13M +86.5% 01 Jul 2023 30 Sep 2023 10-Q 09 Nov 2023
Q2 2023 -$19.1M -$3.81M +$1.36M +26.3% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024
Q1 2023 -$20.4M -$5.39M +$5M +48.1% 01 Jan 2023 31 Mar 2023 10-Q 12 Aug 2024
Q4 2022 -$25.4M -$3.93M +$15.6M +79.9% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024
Q3 2022 -$41M -$5.93M +$10.8M +64.6% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$51.9M -$5.17M +$12.5M +70.7% 01 Apr 2022 30 Jun 2022 10-Q 09 Nov 2023
Q1 2022 -$64.3M -$10.4M +$6.74M +39.4% 01 Jan 2022 31 Mar 2022 10-Q 09 Nov 2023
Q4 2021 -$71.1M -$19.5M -$1.91M -10.8% 01 Oct 2021 31 Dec 2021 10-K 28 Mar 2024
Q3 2021 -$69.2M -$16.8M -$1.25M -8.04% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 -$67.9M -$17.6M -$6.81M -62.9% 01 Apr 2021 30 Jun 2021 10-Q 07 Nov 2022
Q1 2021 -$61.1M -$17.1M -$9.25M -117% 01 Jan 2021 31 Mar 2021 10-Q 07 Nov 2022
Q4 2020 -$51.9M -$17.6M -$11.6M -193% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2021
Q3 2020 -$40.3M -$15.5M -$11.1M -250% 01 Jul 2020 30 Sep 2020 10-Q/A 30 Dec 2021
Q2 2020 -$29.2M -$10.8M -$7.34M -211% 01 Apr 2020 30 Jun 2020 10-Q/A 30 Dec 2021
Q1 2020 -$21.8M -$7.88M -$3.21M -68.8% 01 Jan 2020 31 Mar 2020 10-Q/A 30 Dec 2021
Q4 2019 -$18.6M -$6.02M -$2.21M -58% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2021
Q3 2019 -$16.4M -$4.43M -$640K -16.9% 01 Jul 2019 30 Sep 2019 10-K 01 Mar 2021
Q2 2019 -$15.8M -$3.48M +$1.86M +34.8% 01 Apr 2019 30 Jun 2019 10-K 01 Mar 2021
Q1 2019 -$17.6M -$4.67M +$2.16M +31.7% 01 Jan 2019 31 Mar 2019 10-K 01 Mar 2021
Q4 2018 -$19.8M -$3.81M +$2.43M +38.9% 01 Oct 2018 31 Dec 2018 10-K 20 Feb 2020
Q3 2018 -$22.2M -$3.79M +$3.31M +46.6% 01 Jul 2018 30 Sep 2018 10-K 20 Feb 2020
Q2 2018 -$25.5M -$5.34M +$2.1M +28.2% 01 Apr 2018 30 Jun 2018 10-K 20 Feb 2020
Q1 2018 -$27.6M -$6.83M +$683K +9.09% 01 Jan 2018 31 Mar 2018 10-K 20 Feb 2020
Q4 2017 -$28.3M -$6.24M -$1.04M -20% 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2019
Q3 2017 -$27.3M -$7.1M +$702K +9% 01 Jul 2017 30 Sep 2017 10-K 12 Mar 2019
Q2 2017 -$28M -$7.45M +$972K +11.5% 01 Apr 2017 30 Jun 2017 10-K 12 Mar 2019
Q1 2017 -$28.9M -$7.52M -$198K -2.71% 01 Jan 2017 31 Mar 2017 10-K 12 Mar 2019
Q4 2016 -$28.7M -$5.2M 01 Oct 2016 31 Dec 2016 10-K 12 Mar 2018
Q3 2016 -$7.8M 01 Jul 2016 30 Sep 2016 10-K 12 Mar 2018
Q2 2016 -$8.42M 01 Apr 2016 30 Jun 2016 10-K 12 Mar 2018
Q1 2016 -$7.32M +$1.22M +14.3% 01 Jan 2016 31 Mar 2016 10-K 12 Mar 2018
Q1 2015 -$8.54M -$9.38M -1117% 01 Jan 2015 31 Mar 2015 10-Q 12 May 2015
Q1 2014 $839K 01 Jan 2014 31 Mar 2014 10-Q 12 May 2015

AGILE THERAPEUTICS INC Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$14.5M +$10.9M +43.1% 01 Jan 2023 31 Dec 2023 10-K 28 Mar 2024
2022 -$25.4M +$45.7M +64.2% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024
2021 -$71.1M -$19.2M -37.1% 01 Jan 2021 31 Dec 2021 10-K 28 Mar 2024
2020 -$51.9M -$33.2M -179% 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2023
2019 -$18.6M +$1.17M +5.93% 01 Jan 2019 31 Dec 2019 10-K 30 Mar 2022
2018 -$19.8M +$8.53M +30.1% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021
2017 -$28.3M +$437K +1.52% 01 Jan 2017 31 Dec 2017 10-K 20 Feb 2020
2016 -$28.7M +$1.59M +5.26% 01 Jan 2016 31 Dec 2016 10-K 12 Mar 2019
2015 -$30.3M -$14.3M -88.7% 01 Jan 2015 31 Dec 2015 10-K 12 Mar 2018
2014 -$16.1M -$1.76M -12.3% 01 Jan 2014 31 Dec 2014 10-K 26 Mar 2015
2013 -$14.3M +$8.94M +38.4% 01 Jan 2013 31 Dec 2013 10-K 26 Mar 2015
2012 -$23.3M 01 Jan 2012 31 Dec 2012 10-K 26 Mar 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.